Eli Lilly (LLY) Stock Slips as Pharma Giant Seals $2.88B Merida Biosciences Acquisition

Key Highlights

• Pharmaceutical powerhouse Eli Lilly is purchasing privately owned Merida Biosciences in a deal valued at up to $2.88 billion cash.
• The transaction provides Lilly access to MER511, an experimental therapy for Graves’ disease and thyroid eye disease in early clinical trials.
• Merida’s developmental portfolio features MER769, which targets food allergies, asthma, and additional allergic disorders.
• This buyout comes on the heels of Lilly’s $2.4 billion Orna Therapeutics acquisition completed earlier this year.
• Shares of LLY declined 0.3% during premarket hours Monday after the announcement.

Pharmaceutical leader Eli Lilly revealed on Monday its intention to purchase privately owned Merida Biosciences in an all-cash transaction worth up to $2.88 billion. The agreement features an initial upfront payment combined with performance-based milestone payments, with completion anticipated during the fourth quarter of 2026.

Following the disclosure, LLY stock experienced a 0.3% decline in premarket trading.

Eli Lilly and Company, LLY

Merida specializes in creating biologic treatments designed to selectively eliminate disease-causing antibodies associated with autoimmune and allergic disorders. The company’s primary asset, MER511, is currently undergoing early-phase clinical testing for treating Graves’ disease and thyroid eye disease.

Graves’ disease triggers the thyroid gland to become hyperactive, resulting in excessive hormone production. Thyroid eye disease can cause inflammation, protruding eyes, diplopia, and potential vision impairment.

According to Lilly, preliminary clinical findings demonstrated that MER511 significantly reduced thyroid-stimulating antibodies responsible for both disorders, while maintaining an encouraging early safety record.

Existing therapeutic options for Graves’ disease encompass antithyroid drugs, radioiodine therapy, and surgical intervention. For thyroid eye disease, two treatments have received FDA authorization: Tepezza from Amgen and Lumvoa from Viridian Therapeutics.

Strengthening Immunology Capabilities

The Merida acquisition represents Lilly’s continued strategic expansion within the immunology therapeutic area. Earlier in February 2026, Lilly’s agreed to purchase Orna Therapeutics, which specializes in B-cell-targeted autoimmune treatments, for $2.4 billion cash.

Beyond its lead program, Merida maintains a diverse development portfolio. The company’s MER769 candidate represents an investigational approach for addressing food allergies, asthma, and related allergic conditions, alongside additional early-stage programs focused on renal and immune-related diseases.

“Merida’s lead program is designed to do exactly that,” said Francisco Ramirez-Valle, Lilly’s senior vice president of immunology research and early clinical development, referring to therapies that change the course of disease rather than just its effects.

Aggressive M&A Strategy Continues

Lilly’s acquisition momentum throughout 2026 has significantly exceeded previous years. During the second quarter, the pharmaceutical company finalized purchases of Kelonia Therapeutics and Ajax Therapeutics, both strengthening its hematologic oncology portfolio.

The company’s largest transaction of 2026 closed in late June, when Lilly acquired Centessa Pharmaceuticals for $7.8 billion, gaining access to therapies addressing neurological conditions and sleep-wake disorders such as narcolepsy.

Industry-wide biopharmaceutical merger and acquisition activity through early June 2026 totaled $106 billion spanning 201 deals, based on PitchBook analytics. As the world’s most valuable pharmaceutical company by market capitalization, Lilly has emerged as among the sector’s most aggressive acquirers.

The pharmaceutical giant has financed its acquisition spree primarily through substantial revenues generated by its blockbuster GLP-1 obesity medication franchise, as management seeks to diversify growth opportunities beyond diabetes and weight management.

Subject to standard regulatory approvals and closing requirements, the Merida acquisition is projected to finalize in the fourth quarter of 2026.